Videos

This September 22 Savvy Conversations episode features a conversation on vitiligo and its impact on patients of diverse skin types.

Neuen reviews recent advances in IgAN treatment and findings from a systematic review and meta-analysis guiding their use in clinical practice.

A significant amount of TED cases go undiagnosed due to a lack of routine screening – Khachikian discusses what is needed to address this problem.

New data reveals ritlecitinib's long-term efficacy for alopecia areata, showing sustained hair regrowth in 30% of patients after 3 years.

In this interview at EADV, Hong speaks about his team’s findings on IL-22RA1 antagonism with temtokibart and its impact on atopic dermatitis.

Adolescents with alopecia areata show promising treatment responses, highlighting the need for diverse therapeutic options to improve outcomes.

This interview segment with Bunick at EADV highlights some of the significance of these recent findings on cardiovascular risk and upadacitinib use over 6 years.

Chapman discussed further research to be done with PDT for basal cell carcinoma.

In this EADV interview, Bunick touches on his team’s findings related to risk of VTE, MACE, and malignancy in patients with atopic dermatitis treated with upadacitinib for 6 years.

Le describes growing multidisciplinary conversations around CKM and why cardiovascular health needs to be a central focus of MASH/MASLD care.

This EADV interview featured a discussion with Brittany Craiglow, MD, on the topic of developments in the field of alopecia areata treatment.

In this EADV interview, Chovatiya highlights some of his session’s most notable takeaways regarding current treatments and new data in the atopic dermatitis space.

Chapman discussed the latest findings from a phase 3 study assessing PDT with 10% ALA in people with BCC.

This interview with Amy Paller, MD, highlights the significance of the approval of ruxolitinib for the treatment of pediatric atopic dermatitis.

In this interview at EADV, Pasumarthi highlights her team’s late-breaking data on ritlecitinib’s use among patients with cicatricial alopecias.

This interview segment highlights Song’s risankizumab data covered during the 2025 EADV Congress in Paris.

Harrington and Desai weigh in with their thoughts on the bumetanide approval and how we can continue to battle edema in heart failure.

Saggese explains the importance of effective communication in MASH management and emphasizes the need for more therapies to offer patients.

A recent study reveals diverse real-world data on abrocitinib use for atopic dermatitis.

Eingun James Song, MD, highlights recent phase 4 data on risankizumab for patients with moderate to severe scalp and genital psoriasis.

Shawn Kwatra, MD, highlights his team’s findings presented at EADV on the efficacy of dupilumab in treating prurigo nodularis.

Brogan discusses the various opportunities and challenges that have accompanied recent evolutions in inflammatory bowel disease management.

Arora discusses the results of Bristol Myers Squibb’s observational study and the implications it has for the study of obstructive HCM and cardiology at large.

Stewart reviews clinical pearls for performing rectal exams and explains common mistakes and misdiagnoses as well as how to avoid them.

Moore discusses the importance of individualizing PBC treatment now that multiple second-line therapies are available.

Real-world data show epinephrine nasal spray achieved an 89.2% success rate in treating anaphylaxis, nearly identical to the injection’s response rate.

This episode highlights the challenges of navigating demanding medical careers while raising young children, with insights and practical strategies.

Akin discussed updated data on elenestinib from the HARBOR trial in indolent systemic mastocytosis.